A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation
| Autor: | James Fisher, Todd E. DeFor, Cathryn Jennissen, Mark N. Kirstein, Jessica Knight-Perry, Susie E. Long, Angela R. Smith, Wing T. Chan, Stefanie M Hage |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Antifungal Agents Gastroenterology Article 03 medical and health sciences Dose finding 0302 clinical medicine Age groups Internal medicine medicine Humans Dosing Child Voriconazole Transplantation Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation Hematology Phase i study 030220 oncology & carcinogenesis Cohort Administration Intravenous business Invasive Fungal Infections 030215 immunology medicine.drug |
| Zdroj: | Bone Marrow Transplant |
| ISSN: | 1476-5365 |
| Popis: | To optimize voriconazole dosing in pediatric hematopoietic cell transplantation (HCT), we conducted a phase I study with a modified 3 + 3 dose-escalation followed by an expansion cohort at the maximum tolerated, minimum efficacious dose (MTD/MED). Patients ≤21 years who required voriconazole for prevention or treatment of an invasive fungal infection were assigned to three age groups. Of the 59 evaluable patients, 13 were 100% CV, and clearance increased with age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink